메뉴 건너뛰기




Volumn 34, Issue 3, 2014, Pages 174-179

In silico evaluation for the potential naturally available drugs for breast cancer

Author keywords

4 epidoxorubicin; ADMET; Breast cancer; Breast cancer drugs; ERBB2; HER 2

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; DOCETAXEL; DOCKING PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; EPIRUBICIN; LAPATINIB; LETROZOLE; LIGAND; METHOTREXATE; PACLITAXEL; SALVIANOLIC ACID; TAK 285 1; TAK 285 2; TAMOXIFEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; PROTEIN BINDING;

EID: 84901256559     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2013.868904     Document Type: Article
Times cited : (5)

References (38)
  • 2
    • 67649596590 scopus 로고    scopus 로고
    • National Cancer Institute. Available From [last accessed 4 Nov 2013]
    • National Cancer Institute. Probability of breast cancer in American women. Available from: Http://www.cancer.gov/ cancer topics/ factsheet/Detection/Probability-breast-cancer [last accessed 4 Nov 2013
    • Probability of Breast Cancer in American Women
  • 3
    • 78049485263 scopus 로고    scopus 로고
    • Estimates of worldwide burden of cancer in 2008: Globocan 2008
    • Frlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127: 2893-917
    • (2010) Int J Cancer , vol.127 , pp. 2893-2917
    • Frlay, J.1    Shin, H.R.2    Bray, F.3
  • 4
    • 46049089154 scopus 로고    scopus 로고
    • National Cancer Institute. Available From [last accessed 4 Nov 2013]
    • National Cancer Institute. Breast cancer. Available from: Http:// www.cancer.gov/cancertopics/types/breast [last accessed 4 Nov 2013
    • Breast Cancer
  • 5
    • 79851486664 scopus 로고    scopus 로고
    • Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
    • James R, Thrivenik K, krishnamoorthy L, et al. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer. Indian J Med Res 2011;133:70-5
    • (2011) Indian J Med Res , vol.133 , pp. 70-75
    • James, R.1    Thrivenik, K.2    Krishnamoorthy, L.3
  • 6
    • 34147105901 scopus 로고    scopus 로고
    • Cross-Talk between er and her 2 in breast carcinoma
    • Natasha TR Zora K, Dragica NV. Cross-Talk between ER and Her 2 in breast carcinoma. Arch Oncol 2006;14:146-50
    • (2006) Arch Oncol , vol.14 , pp. 146-150
    • Natasha, T.R.1    Zora, K.2    Dragica, N.V.3
  • 8
    • 56949108012 scopus 로고    scopus 로고
    • Her2-Positive breast cancer: Herceptin and beyond
    • Dean-Colomb W, Esteva FJ. Her2-Positive breast cancer: Herceptin and beyond. Eur J Cancer 2008;44:2806-12
    • (2008) Eur J Cancer , vol.44 , pp. 2806-2812
    • Dean-Colomb, W.1    Esteva, F.J.2
  • 9
    • 0034018946 scopus 로고    scopus 로고
    • Laboratory assessment of the status of her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
    • 10.1136/jcp.53.5.374
    • Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens:comparision of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000;53:374-81. (Pubitemid 30256906
    • (2000) Journal of Clinical Pathology , vol.53 , Issue.5 , pp. 374-381
    • Wang, S.1    Saboorian, M.H.2    Frenkel, E.3    Hynan, L.4    Gokaslan, S.T.5    Ashfaq, R.6
  • 10
    • 0034864813 scopus 로고    scopus 로고
    • Her2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer
    • Menard S,Casalini P, Campiglio M, et al. Her2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001;12:S15-19
    • (2001) Ann Oncol , vol.12
    • Menard, S.1    Casalini, P.2    Campiglio, M.3
  • 11
    • 0022406444 scopus 로고
    • Amplification of a novel v-erbB-related gene in a human mammary carcinoma
    • King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb B-related gene in a human mammary Carcinoma. Science 1985; 229:974-6. (Pubitemid 16248488
    • (1985) Science , vol.229 , Issue.4717 , pp. 974-976
    • King, C.R.1    Kraus, M.H.2    Aaronson, S.A.3
  • 12
    • 0034766736 scopus 로고    scopus 로고
    • Biology of her2 and its importance in breast cancer
    • Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61:1-13. (Pubitemid 33033419
    • (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 1-13
    • Yarden, Y.1
  • 13
    • 0032875428 scopus 로고    scopus 로고
    • Basic science of her-2/neu: A review
    • Hung MC, Lau Y-K. Basic Science of HER 2/neu: A review. Semin Oncol 1999;26:51-9. (Pubitemid 29411433
    • (1999) Seminars in Oncology , vol.26 , Issue.4 SUPPL. 12 , pp. 51-59
    • Hung, M.-C.1    Lau, Y.-K.2
  • 14
    • 0023640312 scopus 로고
    • Proto-oncogenes and humancancers
    • Slamon DJ. Proto-oncogenes and humancancers. N Engl J Med 1987;317:955-7
    • (1987) N Engl J Med , vol.317 , pp. 955-957
    • Slamon, D.J.1
  • 16
    • 0025374582 scopus 로고
    • Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and pI 85 protein expression in human breast cancer cell lines
    • Linnea DR, Duane KJ, Dennis JS, Benita SK. Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and pI 85 protein expression in human breast cancer cell lines. Cancer Res 1990;50:3947-51
    • (1990) Cancer Res , vol.50 , pp. 3947-3951
    • Linnea, D.R.1    Duane, K.J.2    Dennis, J.S.3    Benita, S.K.4
  • 17
    • 0030944455 scopus 로고    scopus 로고
    • ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
    • 10.1093/emboj/16.7.1647
    • Graus-Porta D, Beerli RR, Dalya JM, Hynes NE. ErbB-2 the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55. (Pubitemid 27151960
    • (1997) EMBO Journal , vol.16 , Issue.7 , pp. 1647-1655
    • Graus-Porta, D.1    Beerli, R.R.2    Daly, J.M.3    Hynes, N.E.4
  • 18
    • 0037429725 scopus 로고    scopus 로고
    • The ErbB receptors and their role in cancer progression
    • 10.1016/S0014-4827(02)00099-X
    • Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. (Pubitemid 36331969
    • (2003) Experimental Cell Research , vol.284 , Issue.1 , pp. 99-110
    • Holbro, T.1    Civenni, G.2    Hynes, N.E.3
  • 19
    • 44149098849 scopus 로고    scopus 로고
    • Cytogenetic analysis of HER 1/EGFR, HER 2, HER 3, and HER 4 in 278 breast cancer patients
    • Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis of HER 1/EGFR, HER 2, HER 3, and HER 4 in 278 breast cancer patients. Breast Cancer Res 2008;10:R2
    • (2008) Breast Cancer Res , vol.10
    • Sassen, A.1    Rochon, J.2    Wild, P.3
  • 20
    • 58149260228 scopus 로고    scopus 로고
    • Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma a systematic review
    • Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma. A systematic review. Radiother Oncol 2009;90:1-13
    • (2009) Radiother Oncol , vol.90 , pp. 1-13
    • Offersen, B.V.1    Overgaard, M.2    Kroman, N.3    Overgaard, J.4
  • 21
    • 50249085041 scopus 로고    scopus 로고
    • Patient choice significantly affects mastectomy rates in the treatment of breast cancer
    • Kirby RM, Basit A, Manimaran N. Patient choice significantly affects mastectomy rates in the treatment of breast cancer. Int Semin Surg Oncol 2008;5:20-2
    • (2008) Int Semin Surg Oncol , vol.5 , pp. 20-22
    • Kirby, R.M.1    Basit, A.2    Manimaran, N.3
  • 22
    • 71249086867 scopus 로고    scopus 로고
    • Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2X2 randomised clinical trial in patients with low risk of recurrence
    • German Breast Cancer Study Group (GBSG).
    • Winzer KJ, Sauerberi W, Braun M, et al. German Breast Cancer Study Group (GBSG). Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2X2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2010;46:95-101
    • (2010) Eur J Cancer , vol.46 , pp. 95-101
    • Winzer, K.J.1    Sauerberi, W.2    Braun, M.3
  • 23
    • 78650293742 scopus 로고    scopus 로고
    • Ipsilateral breast recurrence after breast conserving surgery in patients with small (-cm) breast cancer treated with modern adjuvant therapies
    • Siponen ET, Vaalavirata L, Joensuu H, et al. Ipsilateral breast recurrence after breast conserving surgery in patients with small (-cm) breast cancer treated with modern adjuvant therapies. Eur J Surg Oncol 2011;37:15-31
    • (2011) Eur J Surg Oncol , vol.37 , pp. 15-31
    • Siponen, E.T.1    Vaalavirata, L.2    Joensuu, H.3
  • 24
    • 0028857587 scopus 로고
    • Breast and ovarian cancer-specific cytotoxic t lymphocytes recognize the same her2/neu-derived peptide
    • Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-Derived peptide. Proc Natl Acad Sci USA 1995;92: 432-6
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 432-436
    • Peoples, G.E.1    Goedegebuure, P.S.2    Smith, R.3
  • 25
    • 0037102126 scopus 로고    scopus 로고
    • Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a north american trial
    • Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a north american trial. J Clin Oncol 2002;20:3386-95
    • (2002) J Clin Oncol , vol.20 , pp. 3386-3395
    • Osborne, C.K.1    Pippen, J.2    Jones, S.E.3
  • 28
    • 0031444312 scopus 로고    scopus 로고
    • Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells
    • Ahmad N, Feyes DK, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89:1881-6. (Pubitemid 28009824
    • (1997) Journal of the National Cancer Institute , vol.89 , Issue.24 , pp. 1881-1886
    • Ahmad, N.1    Feyes, D.K.2    Nieminen, A.-L.3    Agarwal, R.4    Mukhtar, H.5
  • 30
    • 0031663593 scopus 로고    scopus 로고
    • In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
    • Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93
    • (1998) Clin Cancer Res , vol.4 , pp. 2089-2093
    • Geisler, J.1    King, N.2    Anker, G.3
  • 33
    • 0036091354 scopus 로고    scopus 로고
    • HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil
    • Di Leo A, Gancberg D, Larsimont D, et al. HER-2 Amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16. (Pubitemid 34517647
    • (2002) Clinical Cancer Research , vol.8 , Issue.5 , pp. 1107-1116
    • Di Leo, A.1    Gancberg, D.2    Larsimont, D.3    Tanner, M.4    Jarvinen, T.5    Rouas, G.6    Dolci, S.7    Leroy, J.-Y.8    Paesmans, M.9    Isola, J.10    Piccart, M.J.11
  • 34
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
    • (2007) N Engl J Med , vol.357 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 35
    • 33645278071 scopus 로고    scopus 로고
    • The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters
    • Zhouy Z-T, Yangy Y, Ge J-P. The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters. Carcinogenesis 2006;27:826-32
    • (2006) Carcinogenesis , vol.27 , pp. 826-832
    • Zhouy, Z.-T.1    Yangy, Y.2    Ge, J.-P.3
  • 36
    • 84883045013 scopus 로고    scopus 로고
    • Antitumor activity of tak-285, an investigational, non-pgp substrate her2/egfr kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an her2-positive brain metastasis model
    • Nakayama A, Takagi S, Yusa T, et al. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model. J Cancer 2013;4: 557-65
    • (2013) J Cancer , vol.4 , pp. 557-565
    • Nakayama, A.1    Takagi, S.2    Yusa, T.3
  • 37
    • 33847773775 scopus 로고    scopus 로고
    • Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
    • 10.1093/jnci/djk050
    • Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the royal marsden randomized, double-blinded tamoxifen breast cancer prevention trial. JNCI J Natl Cancer Inst 2007;99:283-90. (Pubitemid 47073491
    • (2007) Journal of the National Cancer Institute , vol.99 , Issue.4 , pp. 283-290
    • Powles, T.J.1    Ashley, S.2    Tidy, A.3    Smith, I.E.4    Dowsett, M.5
  • 38
    • 84860363447 scopus 로고    scopus 로고
    • Evaluation of her-2/ neu status in breast cancer specimens using immunohistochemistry (ihc) & fluorescence in-situ hybridization (fish) assay
    • Goud KI, Dayakar S, Vijayalaxmi K, et al. Evaluation of HER-2/ neu status in breast cancer specimens using Immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res 2012;135:312-17
    • (2012) Indian J Med Res , vol.135 , pp. 312-317
    • Goud, K.I.1    Dayakar, S.2    Vijayalaxmi, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.